Treats acute lymphoblastic leukemia. ANDA 89342, held by Hikma Pharmaceuticals. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 89342 (Methotrexate Sodium), held by Hikma Pharmaceuticals, was first approved by FDA on Sep 16, 1986, with 20 approved supplements and 0 published complete response letters.
Methotrexate Injection is a folate analog metabolic inhibitor indicated for: The following neoplastic diseases for the: Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia Treatment of adult and pediatric patients with non-Hodgkin lymphoma Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen Treatment of adults with breast cancer as part of a combination chemotherapy regimen Treatment of adults with squamous cell carcinoma of the head and neck as single-agent Treatment of adults with gestat…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 200MG BASE/8ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Oct 25, 2021 | Supplement 38Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Supplement 36Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Supplement 34Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 32Labeling | Approved | None posted |
| Apr 25, 2011 | Supplement 29Labeling | Approved | None posted |
| Apr 3, 2001 | Supplement 21Manufacturing | Approved | None posted |
| Sep 19, 2000 | Supplement 20Labeling | Approved | None posted |
| May 24, 2000 | Supplement 17Labeling | Approved | None posted |
| Nov 17, 1999 | Supplement 16Labeling | Approved | None posted |
| Sep 22, 1999 | Supplement 15Labeling | Approved | None posted |
| Jan 28, 1999 | Supplement 14Labeling | Approved | None posted |
| Jun 11, 1998 | Supplement 13Labeling | Approved | None posted |
| Aug 11, 1995 | Supplement 12Manufacturing | Approved | None posted |
| May 12, 1995 | Supplement 11Manufacturing | Approved | None posted |
| Nov 5, 1993 | Supplement 10Manufacturing | Approved | None posted |
| May 3, 1993 | Supplement 9Manufacturing | Approved | None posted |
| Jan 15, 1993 | Supplement 8Manufacturing | Approved | None posted |
| Apr 18, 1990 | Supplement 7Labeling | Approved | None posted |
| Apr 25, 1988 | Supplement 3Manufacturing | Approved | None posted |
| Jul 20, 1987 | Supplement 1Manufacturing | Approved | None posted |
| Sep 16, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters